Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • califlyonjkwall califlyonjkwall Sep 26, 2013 11:46 AM Flag

    JMP Securities reiterates an Outperform rating on Synta tgt 18

    Outlook for Synta Pharma ganetespib still positive, says JMP Securities
    After Infinity's (INFI) Hsp90 inhibitor, retaspimycin, failed its Phase II NSCLC study, JMP Securities notes that retaspimycin and Synta's (SNTA) ganetespib share a similar mechanism of action. Nonetheless JMP Securities reports that the drugs address patients with different types of cancers, and the firm thinks that ganetespib is more potent than retaspimycin. JMP Securities reiterates an Outperform rating on Synta.

 
SNTA
0.2633-0.0167(-5.96%)1:34 PMEDT